Atherotech to Exhibit VAP Cholesterol Test at AHA 2008

November 7, 2008 - Atherotech Inc. announced it will be exhibiting its VAP Cholesterol Test at the American Heart Association Scientific Sessions 2008, Nov. 8-12 in New Orleans.
The VAP (vertical auto profile) Test is reportedly the only commercially available advanced lipid profile that routinely reports all three lipoprotein parameters - LDL, non-HDL and apoB - considered necessary by the 2008 expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test.
The VAP Test reports all 15 lipoprotein measurements with a single test, and unlike other lipid profiles, it directly measures LDL and HDL and includes Lp(a) and apoB as part of its standard test. Atherotech has announced plans to add apolipoprotein A-1 (apoA1) to its reporting in early 2009. ApoA1 is the main component of protective HDL cholesterol and studies have shown that the apoB:apoA1 ratio may correlate better with increased risk of coronary artery disease (CAD) than total cholesterol and LDL:HDL ratio.
Atherotech said the VAP Cholesterol Test has been shown to identify significantly more patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test).
For more information: www.thevaptest.com